Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of MEDITOXIN vs BOTOX in Idiopathic Overactive Bladder
NCT03371342Phase 1Completed
- Sponsor
- Medytox Inc.
- Start
- Dec 2017
- Primary completion
- May 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Meditoxin in overactive bladder (OAB) (2 arms), sponsored by Medytox Inc. Primary endpoint: Change from baseline in adverse events at 12 weeks. Started Dec 2017; status: completed.
02
Drugs
Meditoxin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT03371342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03371342.